과제정보
The authors sincerely thank the LEDIOS Registry sites and staff for their commitment and contributions to the study. The authors also thank Ji-Su Goag from Daiichi Sankyo Korea for their support of the trial.
참고문헌
- Yamashita T, Suzuki S, Inoue H, et al. Two-year outcomes of more than 30 000 elderly patients with atrial fibrillation: results from the All Nippon AF In the Elderly (ANAFIE) registry. Eur Heart J Qual Care Clin Outcomes 2022;8:202-13.
- Chao TF, Chiang CE, Liao JN, Chen TJ, Lip GY, Chen SA. Comparing the effectiveness and safety of nonvitamin k antagonist oral anticoagulants and warfarin in elderly Asian patients with atrial fibrillation: a nationwide cohort study. Chest 2020;157:1266-77.
- Henrard S, Vandenabeele C, Marien S, Boland B, Dalleur O. Underuse of anticoagulation in older patients with atrial fibrillation and CHADS2 score ≥ 2: are we doing better since the marketing of direct oral anticoagulants? Drugs Aging 2017;34:841-50.
- Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. Circ J 2014;78:2166-72.
- Okumura K, Akao M, Yoshida T, et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 2020;383:1735-45.
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093-104.
- Steffel J, Ruff CT, Yin O, et al. Randomized, double-blind comparison of half-dose versus full-dose edoxaban in 14,014 patients with atrial fibrillation. J Am Coll Cardiol 2021;77:1197-207.
- Kim JY, Choi EK, Lim HE, Oh YS, Cho Y, On YK. Outcomes of on-label reduced-dose edoxaban in patients with atrial fibrillation: the LEDIOS registry. J Korean Med Sci 2022;37:e335.
- Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005;3:692-4.
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021;23:1612-76.
- Lee SR, Lee YS, Park JS, et al. Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation. Yonsei Med J 2019;60:277-84.
- Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 2019;394:1335-43.
- Chao TF, Chiang CE, Chan YH, et al. Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. Heart Rhythm 2021;18:871-7.
- Tsai CT, Liao JN, Chen SJ, Jiang YR, Chen TJ, Chao TF. Non-vitamin K antagonist oral anticoagulants versus warfarin in AF patients ≥ 85 years. Eur J Clin Invest 2021;51:e13488.
- Chan YH, Lee HF, See LC, et al. Effectiveness and safety of four direct oral anticoagulants in Asian patients with nonvalvular atrial fibrillation. Chest 2019;156:529-43.
- Bronnum Nielsen P, Larsen TB, Gorst-Rasmussen A, Skjoth F, Rasmussen LH, Lip GY. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest 2015;147:1651-8.
- Chao TF, Liu CJ, Liao JN, et al. Use of oral anticoagulants for stroke prevention in patients with atrial fibrillation who have a history of intracranial hemorrhage. Circulation 2016;133:1540-7.
- Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol 2017;69:2779-90.